warrants are at a higher price than the offering and Oncosec does not expect them to be executed until there is a market for them so I don't expect this to be dilution until we have another runup into TNBC data at the SAABS conference in December. If that shows significant response rates at 6 months evaluation time than I expect the shares to be much higher. Now consensus price targets are $20 for ONCS.